. 2022 May 3;22:117. doi: 10.1186/s12902-022-01027-1

Table 2.

Preference of different LT4 formulations in various clinical scenarios of cases with hypothyroidism

	Tablets	Soft-gel capsules	Liquid solution	I expect no major changes with the different formulations
Interfering drugs may influence the stability of therapy. Which LT4 preparation is in your experience least likely to be subject to variable absorption?	85 (54.1%)	10 (6.4%)	5 (3.2%)	57 (36.3%)
Which of the following preparations of LT4 would you prescribe in case of first diagnosis of hypothyroidism when the patient self-reports intolerance to various foods raising the possibility of celiac disease, malabsorption, lactose intolerance, or intolerance to common excipients	89 (56.7%)	20 (12.7%)	12 (7.6%)	36 (22.9%)
Which of the following preparations of LT4 would you prescribe for a patient established on LT4 who has unexplained poor biochemical control of hypothyroidism?	80 (50.9%) *	18 (11.5%)	11 (7.0%)	48 (30.6%)
Which of the following preparations of LT4 would you prescribe for a patient with poor biochemical control who is unable (due to busy lifestyle) to take LT4 fasted and separate from food/drink?	76 (48.4%)	17 (10.8%)	17 (10.8%)	47 (29.9%)
Which of the following preparations of LT4 would you prescribe for a patient established on LT4 tablets who has good biochemical control of hypothyroidism but continues to have symptoms?	81 (51.6%) *	9 (5.7%)	1 (0.6%)	66 (42.0%)

Tablets

Soft-gel capsules

Liquid solution

I expect no major changes with the different formulations

Interfering drugs may influence the stability of therapy. Which LT4 preparation is in your experience least likely to be subject to variable absorption?

(54.1%)

(6.4%)

(3.2%)

(36.3%)

Which of the following preparations of LT4 would you prescribe in case of first diagnosis of hypothyroidism when the patient self-reports intolerance to various foods raising the possibility of celiac disease, malabsorption, lactose intolerance, or intolerance to common excipients

(56.7%)

(12.7%)

(7.6%)

(22.9%)

Which of the following preparations of LT4 would you prescribe for a patient established on LT4 who has unexplained poor biochemical control of hypothyroidism?

(50.9%) *

(11.5%)

(7.0%)

(30.6%)

Which of the following preparations of LT4 would you prescribe for a patient with poor biochemical control who is unable (due to busy lifestyle) to take LT4 fasted and separate from food/drink?

(48.4%)

(10.8%)

(29.9%)

Which of the following preparations of LT4 would you prescribe for a patient established on LT4 tablets who has good biochemical control of hypothyroidism but continues to have symptoms?

(51.6%) *

(5.7%)

(0.6%)

(42.0%)

^*tablets form another manufacturer

LT4: levothyroxine